       Document 0667
 DOCN  M9620667
 TI    Guidelines for the use of zidovudine in pregnant women with HIV
       infection.
 DT    9602
 AU    De Santis M; Noia G; Caruso A; Mancuso S; Department of Obstetrics and
       Gynaecology, Catholic University of; the Sacred Heart, Rome, Italy.
 SO    Drugs. 1995 Jul;50(1):43-7. Unique Identifier : AIDSLINE MED/96078258
 AB    Zidovudine therapy seems to be effective for reducing vertical
       transmission of HIV infection and preventing paediatric AIDS. Besides
       those cases in which it is indicated, zidovudine plays an important role
       in safeguarding maternal well-being. Even though no data indicating
       teratogenic effect of this drug exist, its use during the first
       trimester should be limited to those cases where it is absolutely
       indicated. All undergoing this therapy should be informed that no
       information regarding the long term effects of this drug are available
       yet. Further controlled studies are necessary if this drug is to be used
       in those cases where it could actually be of benefit.
 DE    Disease Transmission, Vertical/PREVENTION & CONTROL  Female  Guidelines
       Human  HIV Infections/*DRUG THERAPY/TRANSMISSION  Maternal-Fetal
       Exchange  Pregnancy  Pregnancy Complications, Infectious/*DRUG THERAPY
       Zidovudine/ADVERSE EFFECTS/PHARMACOKINETICS/*THERAPEUTIC USE  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

